Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis

Mistiaen, Wilhelm; Cauwelaert, P. Van; Muylaert, P.; Sys, Stanislas U.; Harrisson, F.; Bortier, Hilde

doi:10.1016/j.jtcvs.2003.11.010

Cited by 25 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies reported on the predictors for thromboembolism after AVR on long-term and n o n e r e p o r t e d o n s u c h e v e n t s o n s h o r t -t e rm. The short-term thromboembolic events, however, have their importance since these are a predictor for future events (21). A preoperative CVA seemed to have a comparable significance (21-24) for long-term events.…”

Section: Thromboembolic Eventsmentioning

confidence: 95%

“…Carotid artery disease could be a matter for debate. In some series (23,24), it was identified as a predictor for thromboembolism, in other series, this was not (21). A Doppler-duplex investigation is a reliable tool for the detection of lesions and is routinely performed in some institutions.…”

Section: Thromboembolic Eventsmentioning

confidence: 99%

“…However, it is also an indication for anticoagulation, which might cloud the effect of AF. In some series, AF was identified as a predictor (28), in others not (21,24). It is by no means certain that risk factors for long-term thromboembolic events could be used to predict the occurrence of such events on short term.…”

Section: Thromboembolic Eventsmentioning

confidence: 99%

“…Moreover, all these predictors indicate that the sources of thromboembolic events are multiple. Hence thromboembolism cannot be considered as entirely valve related (21,29), but also as patient related.…”

Section: Thromboembolic Eventsmentioning

confidence: 99%

See 3 more Smart Citations

The 30 Day Complication Rate After Aortic Valve Replacement with a Pericardial Valve in a Mainly Geriatric Population

Mistiaen¹

2012

Special Topics in Cardiac Surgery

View full text Add to dashboard Cite

Section: Thromboembolic Eventsmentioning

confidence: 95%

Section: Thromboembolic Eventsmentioning

confidence: 99%

Section: Thromboembolic Eventsmentioning

confidence: 99%

Section: Thromboembolic Eventsmentioning

confidence: 99%

See 2 more Smart Citations

The 30 Day Complication Rate After Aortic Valve Replacement with a Pericardial Valve in a Mainly Geriatric Population

Mistiaen¹

2012

Special Topics in Cardiac Surgery

View full text Add to dashboard Cite

“…A few retrospective studies and two randomized trials have examined the effects of various regimens on the incidence of postoperative thromboembolisms and hemorrhages after AVR with bioprostheses [22,[35][36][37][38][39][40][41][42][43][44][45][46]. Heras et al observed an inordinately high rate of early thromboembolic events in patients who were not anticoagulated, particularly after MVR in the first 10 days postoperatively [22].…”

Section: Literature Reviewmentioning

confidence: 99%

Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue

Colli

Verhoye

Leguerrier

et al. 2007

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

Improvements in the performance and longevity of biological valve prostheses have steadily increased their rates of implantation in recent years. Aortic bioprostheses, which are commonly used in the elderly or when the risks of anticoagulating are high, have generally been associated with low rates of long-term complications. Freedom from anticoagulation, therefore, represents the main theoretical advantage of biological, compared with mechanical, aortic prostheses. While a variety of anticoagulant and antiplatelet drug regimens have been described, a precise antithrombotic protocol for the early postoperative period after bioprosthetic aortic valve replacement has not been developed. There are also important differences between the international guidelines published. This review examines the clinical evidence concerning the use of vitamin K antagonist and antiplatelet therapy in the early management of the antithrombotic complications after bioprosthetic aortic valve replacement.

show abstract

Association of Warfarin Therapy Duration After Bioprosthetic Aortic Valve Replacement With Risk of Mortality, Thromboembolic Complications, and Bleeding

Mérie¹,

Køber²,

Olsen³

et al. 2012

JAMA

203

View full text Add to dashboard Cite

Context The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined. Objective To perform a nationwide study of the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents, and cardiovascular deaths after bioprosthetic AVR surgery. Design, Setting, and Participants Through a search in the Danish National Patient Registry, 4075 patients were identified who had bioprosthetic AVR surgery performed between January 1, 1997, and December 31, 2009. Concomitant comorbidity and medication were retrieved. Poisson regression models were used to determine risk. Main Outcome Measures Incidence rate ratios (IRRs) of strokes, thromboembolic events, cardiovascular deaths, and bleeding incidents by discontinuing warfarin as opposed to continued treatment 30 to 89 days, 90 to 179 days, 180 to 364 days, 365 to 729 days, and at least 730 days after surgery. Results The median duration of follow-up was 6.57 person-years. Estimated rates of events per 100 person-years in patients not treated with warfarin compared with those treated with warfarin with comparative absolute risk were 7.00 (95% CI,

show abstract

Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis

Cited by 25 publications

References 20 publications

The 30 Day Complication Rate After Aortic Valve Replacement with a Pericardial Valve in a Mainly Geriatric Population

The 30 Day Complication Rate After Aortic Valve Replacement with a Pericardial Valve in a Mainly Geriatric Population

Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue

Association of Warfarin Therapy Duration After Bioprosthetic Aortic Valve Replacement With Risk of Mortality, Thromboembolic Complications, and Bleeding

Contact Info

Product

Resources

About